Feedback
Settings

Settings

Goto Application

4,721,835 results
Offices all Languages Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C07

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 472,184
1.112023003758Rückgewinnungsverfahren für die Abfallflüssigkeit des absorbierten Lösungsmittels und CO2-Abscheidungsverfahren
DE - 03.07.2025
Int.Class C07C 213/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
CACYCLIC OR CARBOCYCLIC COMPOUNDS
213Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
10Separation; Purification; Stabilisation; Use of additives
 Appl.No 112023003758 Applicant HUANENG CLEAN ENERGY RESEARCH INSTITUTE Inventor Liu Rong

Die vorliegende Anmeldung betrifft ein Rückgewinnungsverfahren für die Abfallflüssigkeit des absorbierten Lösungsmittels und ein CO2-Abscheidungsverfahren. Das Rückgewinnungsverfahren umfasst: Bereitstellen einer gemischten Aufschlämmung eines Adsorptionsmittels und einer Abfallflüssigkeit des absorbierten Lösungsmittels; und die gemischte Aufschlämmung wird sowohl unter Ultraschall- als auch unter Versiegelungsbedingungen bei 60 ∼ 150°C umgesetzt; wobei das Adsorptionsmittel ein fester Abfall ist, der eine alkalische Substanz enthält. Diese Anwendung verwendet feste Abfälle, die alkalische Substanzen enthalten, als Adsorptionsmittel, um die Abfallflüssigkeit des absorbierten Lösungsmittels zu behandeln, die toxisches und krebserregendes Diethylenglykol und andere schädliche Substanzen, die durch Selbstpolymerisation in der absorbierenden Lösungsmittelabfallflüssigkeit gebildet werden, auf den festen Abfällen adsorbieren kann, wobei die Entfernungsrate mehr als 88 % erreichen kann. Nach dieser Behandlung kann die entstehende Abfallflüssigkeit des absorbierten Lösungsmittels recycelt werden. Darüber hinaus werden feste Abfälle als Adsorptionsmittel verwendet, wobei die Produktionskosten niedrig sind und die Abfälle auch für feste Abfälle verwendet werden können.

2.WO/2025/137954PHOTO-PIEZO-COUPLED CATALYTIC REDUCTION OF CARBON DIOXIDE AT DISLOCATIONS IN A CRYSTALLINE CATALYST
WO - 03.07.2025
Int.Class B01J 35/39
BPERFORMING OPERATIONS; TRANSPORTING
01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
35Catalysts, in general, characterised by their form or physical properties
30characterised by their physical properties
39Photocatalytic properties
 Appl.No PCT/CN2023/142479 Applicant TECHNISCHE UNIVERSITAET DARMSTADT Inventor ROEDEL, Juergen
The present disclosure relates to a method of photo-piezo-coupled catalytic reduction of carbon dioxide to ethanol at dislocations created by plastic deformation in a barium titanate single crystal and to a setup comprising the photo-piezo catalyst having dislocations.
3.WO/2025/139979CHIMERIC ANTIGEN RECEPTOR TARGETING LY6G6D AND USE THEREOF
WO - 03.07.2025
Int.Class C07K 19/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
19Hybrid peptides
 Appl.No PCT/CN2024/140478 Applicant SUNSHINE LAKE PHARMA CO., LTD. Inventor CHEN, Shiyou
Provided are a chimeric antigen receptor targeting Ly6G6D and the use thereof. Specifically, provided is a CAR that can specifically bind to Ly6G6D, which contains an Ly6G6D binding domain, a transmembrane domain, a co-stimulatory domain and an intracellular signal transduction domain. Further provided is the use of the CAR in the treatment of diseases or conditions related to the expression of Ly6G6D.
4.WO/2025/140489MULTISPECIFIC ANTIBODIES AND USES THEREOF
WO - 03.07.2025
Int.Class C07K 19/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
19Hybrid peptides
 Appl.No PCT/CN2024/142997 Applicant VIBRANT PHARMA LIMITED Inventor WANG, Luquan
Provided are multispecific antibodies (e.g., bispecific antibodies or trispecific antibodies) or antigen-binding fragments thereof. In one aspect, the multispecific antibodies or antigen-binding fragments thereof can bind to a T cell antigen (e.g., CD3) and/or one or two tumor-associated antigens (e.g., CAIX, EGFR), or a combination thereof.
5.WO/2025/140504T CELL RECEPTOR TARGETING POLYPEPTIDE WITH KRAS G12V MUTATION AND USE OF T CELL RECEPTOR
WO - 03.07.2025
Int.Class C07K 14/725
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
725T-cell receptors
 Appl.No PCT/CN2024/143046 Applicant IMMUXELL BIOTECH LTD. Inventor HU, Hong-Ming
Provided in the present invention are a T cell receptor targeting a polypeptide with a KRAS G12V mutation and the use of the T cell receptor. The T cell receptor molecule of the present invention specifically targets the KRAS G12V mutation, and the CDR3 sequence of the α chain variable region of the T cell receptor molecule contains CAVNPNTGNQFYF (SEQ ID NO: 1) or a mutant of SEQ ID NO: 1, and/or the CDR3 sequence of the β chain variable region contains CASSQDYGPQETQYF (SEQ ID NO: 2) or a mutant of SEQ ID NO: 2. Further provided in the present invention are a nucleic acid molecule encoding the T cell receptor molecule, a multivalent complex and dual-targeting protein molecule containing the T cell receptor molecule, a nucleic acid construct, a cell expressing the T cell receptor molecule, etc.
6.WO/2025/140279QUATERNARY AMMONIUM COMPOUND AND PHARMACEUTICAL USE THEREOF
WO - 03.07.2025
Int.Class C07D 401/12
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02containing two hetero rings
12linked by a chain containing hetero atoms as chain links
 Appl.No PCT/CN2024/142210 Applicant SHANGHAI SENHUI MEDICINE CO., LTD. Inventor ZHU, Lingjian
The present disclosure relates to a quaternary ammonium compound and a pharmaceutical use thereof. Specifically, the present disclosure relates to a compound represented by formula IA or a pharmaceutically acceptable salt thereof, each substituent being as defined in the description.
7.WO/2025/140069APPLICATION OF REDUCING AGENT IN PEROXIDASE CATALYTIC REACTION
WO - 03.07.2025
Int.Class C12N 9/02
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
9Enzymes, e.g. ligases (6.); Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating, or purifying enzymes
02Oxidoreductases (1.), e.g. luciferase
 Appl.No PCT/CN2024/141277 Applicant HUBEI UNIVERSITY Inventor LI, Aitao
Disclosed in the present invention is an application of a reducing agent in a heme peroxidase catalytic reaction. The reducing agent is selected from ascorbic acid, dehydroascorbic acid, gallic acid and pyrogallic acid. The reducing agent has a significant promotion effect on oxidation reaction and hydroxylation reaction catalyzed by heme peroxidase.
8.WO/2025/140594ASYMMETRIC CATIONIC LIPID CONTAINING MULTIPLE TERTIARY AMINES
WO - 03.07.2025
Int.Class C07D 295/13
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
295Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
04with substituted hydrocarbon radicals attached to ring nitrogen atoms
12substituted by singly or doubly bound nitrogen atoms
125with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
13to an acyclic saturated chain
 Appl.No PCT/CN2024/143282 Applicant XIAMEN SINOPEG BIOTECH CO., LTD Inventor LIN, Minggui
The present invention belongs to the field of drug delivery. Provided is an asymmetric cationic lipid containing multiple tertiary amines, of which the structure is shown as a general formula (1), wherein the definition of each symbol is consistent with that in the description. In the present invention, a degradable group is introduced into a proper position of the cationic lipid, and the presence of the degradable group enables an LNP-drug composition prepared from the cationic lipid to be degradable in endosomes at a proper time and to have small cytotoxicity, thereby solving the problem that in the prior art, LNP-drug compositions prepared from non-degradable lipids will accumulate in endosomes and acidify the endosomal environment, which hinders the endosomal escape of drugs (such as mRNAs) and causes that the drugs delivered into cells fail to sufficiently exert the therapeutic effects. The cationic lipid in the present invention uses a heterofunctionalized piperazine-containing small molecule as a raw material, involves a simple preparation process and a lower cost, and is more green and environmentally-friendly. An LNP-mRNA composition prepared from the cationic lipid has the advantages of low toxicity, high biocompatibility, high cell transfection, etc.
9.WO/2025/140654ANTI-CDH17 ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF AND USE THEREOF
WO - 03.07.2025
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
 Appl.No PCT/CN2024/143461 Applicant GUANGDONG FAPON BIOPHARMA INC. Inventor ZHANG, Yibo
An anti-CDH17 antibody or an antigen-binding fragment thereof and the use thereof. The antibody can specifically bind to one or more extracellular domains in extracellular domains 1-7 of CDH17, has an ADCC activity, and can mediate cell endocytosis, thereby providing a new possibility for the treatment and/or prevention of cancers.
10.WO/2025/140609METHOD FOR CONSTRUCTING CELL WHICH PRODUCES DEFUCOSYLATED PROTEIN AND USE OF CELL
WO - 03.07.2025
Int.Class C07K 14/47
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
46from vertebrates
47from mammals
 Appl.No PCT/CN2024/143321 Applicant WUXI BIOLOGICS (SHANGHAI) CO., LTD. Inventor ZHOU, Yangfang
Provided is a method for constructing a cell which produces defucosylated protein using a zinc finger nuclease which contains a zinc finger protein capable of binding to the FUT8 gene in a targeted manner and a DNA cleavage domain or cleavage half-domain. Also provided are a polynucleotide which encodes the zinc finger protein and the zinc finger nuclease, and a cell containing the polynucleotide and the zinc finger nuclease.
# -